INTRODUCTION
Stem cell or solid organ transplantation (SOT) is essential treatments for patients with hematological malignancies or organ failure. Treatment success can be limited by infectious complications caused by common pathogens such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), BK virus (BKV) or adenovirus (ADV) that arise as a result of profound immunosuppression after transplantation. [1] [2] [3] Antiviral drugs given either prophylactically or as early therapy for patients with detectable viral loads are an effective strategy for reducing viral infections. [4] [5] [6] However, long-term treatment with these drugs is associated with significant toxicity, expense and the appearance of drug-resistant virus isolates, which ultimately results in treatment failure. [7] [8] [9] Cellular immunotherapy has emerged as an effective alternative treatment that can prevent or reduce virusassociated transplant complications while being associated with much lower toxicity. [10] [11] [12] [13] [14] [15] [16] [17] One of the major limitations of autologous or donor-derived T-cell therapy is that the process of generating these effector cells often takes many weeks or months. This limits the use of this approach therapeutically, because the patients often succumb to progressive disease or lose their graft before the T-cells are ready for infusion. Ideally, a T-cell therapy that can be offered as an "off-the-shelf" treatment would be more suitable for these patients. A second limitation is that T-cell preparations often only target a single pathogen which restricts their utility for patients presenting with multiple infections and makes the generation of T-cell banks more laborious and costly. While recent studies have successfully developed strategies to expand multivirus-specific T-cells, [18] [19] [20] one major limitation in the manufacture of these effector cells is that the precise epitope specificity of T-cells expanded using a complex mixture of synthetic peptides remains poorly defined. Moreover, the use of mixtures of overlapping peptides from multiple antigens increases the potential risk of expansion of allogeneic T-cells which may be reactive against engrafted organ. This is particularly relevant for SOT patients where the risk of graft rejection by allogeneic T-cells is much higher when compared with stem cell transplant recipients. To overcome these limitations, we have developed a novel replication-deficient adenoviral antigen presentation system which encodes multiple human leukocyte antigen (HLA) class I-restricted minimal T-cell epitopes from EBV, CMV, BKV, and ADV as a polyepitope protein (referred to as Ad-MvP). We demonstrate that the Ad-MvP platform can be used for the rapid expansion of multivirus-specific cytotoxic T-cells from SOT recipients following Received 8 June 2016; accepted 11 July 2016 Viral infections including cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus are a common and predictable problem in transplant recipients. While cellular immune therapies have been successfully used to tackle infectious complications in transplant recipients, manufacturing immunotherapies to address the multitude of possible pathogens can be technically challenging and labor-intensive. Here we describe a novel adenoviral antigen presentation platform (Ad-MvP) as a tool for rapid generation of multivirus-specific T-cells in a single step. Ad-MvP encodes 32 CD8+ T-cell epitopes from cytomegalovirus, Epstein-Barr virus, adenovirus, and BK virus as a contiguous polyepitope. We demonstrate that Ad-MvP vector can be successfully used for rapid in vitro expansion of multivirus-specific T-cells from transplant recipients and in vivo priming of antiviral T-cell immunity. Most importantly, using an in vivo murine model of Epstein-Barr virus-induced lymphoma, we also show that adoptive immunotherapy with Ad-MvP expanded autologous and allogeneic multivirus-specific T-cells is highly effective in controlling Epstein-Barr virus tumor outgrowth and improving overall survival. We propose that Ad-MvP has wide ranging therapeutic applications in greatly facilitating in vivo priming of antiviral T-cells, the generation of third-party T-cell banks as "off-the-shelf" therapeutics as well as autologous T-cell therapies for transplant patients. single stimulation and that these T-cells are highly effective in controlling virus-associated B cell lymphoma. In addition, Ad-MvP can also be used successfully for priming and/or boosting multivirusspecific T-cells in vivo. Use of the Ad-MvP vector will greatly facilitate the rapid production of multivirus-specific T-cell banks to make autologous or "off-the-shelf" T-cell therapy readily available for transplant patients.
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ReSUlTS
Single stimulation with Ad-MvP is sufficient to expand polyfunctional multivirus specific T-cells from transplant recipients In the first set of experiments, we explored the potential application of the Ad-MvP antigen presentation system for transplant recipients. We recruited a cohort of SOT recipients who had either ongoing or a previous history of recurrent viral reactivation/disease (CMV, EBV or BKV; Table 1 ). Peripheral blood mononuclear cells (PBMC) from these SOT recipients were stimulated with Ad-MvP ( Figure 1 ) at a multiplicity of infection at 10:1 and then cultured for 14 days. Representative data from two different transplant recipients presented in Figure 2a shows that a single stimulation with Ad-MvP was sufficient to induce the rapid expansion of T-cells specific for ADV, BKV, CMV, and EBV epitopes. T-cells expanded from SOT33 showed strong reactivity toward CMV and EBV, while T-cells expanded from SOT15 showed strong reactivity against CMV but also EBV, BKV, and ADV. A comprehensive summary of T-cell expansions following Ad-MvP stimulation from 14 SOT recipients is presented in Figure  2b . These analyses showed that CMV, BKV, EBV, and ADV-specific T-cell expansions were observed in 86, 71, 86, and 29% of SOT patients respectively (Figure 2b ). More importantly, the majority of these in vitro expanded T-cells showed a polyfunctional profile ( Figure 2c ). Taken together, these studies showed that Ad-MvP is highly efficient in expanding multivirus-specific T-cells from transplant recipients and this expansion is not impacted by underlying immunosuppression or ongoing viral reactivation/disease.
In vivo priming of multivirus-specific T-cells with Ad-MvP
In addition to the potential application of Ad-MvP as a tool for in vitro expansion of pre-existing memory/effector T-cells, using a mouse model we also explored the utility of this vector for in vivo priming of multivirus-specific T-cells in seronegative transplant recipients/ donors. Transgenic mice expressing the HLA A*0201 allele (referred to as HHD II mice) were immunized with Ad-MvP (0.5 × 10 8 pfu/mouse) and then one group was boosted with the same dose on day 21. On day 50 postimmunization, these mice were assessed for antigenspecific T-cell responses. While ex vivo analysis revealed strong T-cell response to EBV epitopes and a low or undetectable response toward epitopes from CMV, BKV, and ADV, a 6-240 fold increase in antigenspecific T-cells was observed following in vitro stimulation with BKV, ADV, CMV, or EBV-specific HLA-A*0201-restricted peptide pools (Figure 3a) . A comprehensive summary of multiple HLA-A2-restricted T-cell responses in HHD II mice following Ad-MvP prime alone and prime-boost immunization is shown in Figure 3b . This analysis also showed that while in both the prime alone and prime-boost setting EBV-specific T-cell responses were the dominant component of ex vivo analysis, a significant change in the composition of antigen-specific T-cells was observed following in vitro stimulation. Taken together, these experiments clearly demonstrated that Ad-MvP vector is highly efficient in inducing multivirus-specific T-cells in vivo.
Expansion of multivirus-specific T-cells from healthy donors with Ad-MvP for third-party T-cell bank While autologous T-cell therapy has been successfully used to treat many SOT recipients, many patients are not amenable to this therapy due to severe lymphopenia or transplant-related clinical 
DISCUSSION
T-cell therapy has emerged as an effective treatment tool for viral morbidity and mortality after transplant that provides an alternative to costly prophylactic/pre-emptive antiviral therapy which is often limited by toxicity and resistance. 10, 12, 18, [21] [22] [23] [24] However, transplant patients are often vulnerable to multiple infections and one challenge for the broader application of T-cell therapy is the number of pathogens that can be targeted. [25] [26] [27] [28] We describe here a novel antigen presenting platform designed to stimulate T-cell responses to four common pathogens (CMV, EBV, BKV, and ADV) which have been identified as the major causes of viral complications after transplant. The Ad-MvP platform encodes multiple CD8 + T-cell epitopes from the four different viruses as a polyepitope protein. We demonstrate that stimulation with Ad-MvP consistently achieved twofold to 10-fold expansions of multivirus-specific T-cells both from healthy volunteers as well as transplant patients who have been heavily pretreated with immunosuppressants and have ongoing EBV or CMV-associated clinical complications. Furthermore, we show that both autologous and allogeneic Ad-MvP T-cells can control the growth of EBV-associated lymphoma in a xenogeneic Recent studies from a number of groups have begun to explore the potential application of multivirus-specific T-cells for the treatment of a range of viral diseases in transplant patients. 16, 17, 29 The initial protocols established to generate multivirus-specific T-cells were very laborious and dependent upon the production of EBV-transformed lymphoblastoid cells as a source of antigen presenting cells (APCs) for repeated antigenic stimulation. More recent protocols have refined these approaches and now typically employ a single stimulation with pools of overlapping peptide libraries from immunodominant viral antigens. These multivirus-specific T-cells expanded with peptide libraries were recently used in stem cell transplant patients and provided a 94% virological and clinical response rate. 30 While this approach has accelerated the production of multivirus-specific T-cells, precise characterization of epitope specificity of these T-cell populations may remain a challenge due to the complexity of the antigenic stimuli used. In contrast, the Ad-MvP vector simplifies the characterization of the clinical product by using a polyepitope of fully defined HLA-restricted peptide epitopes. In addition, the Ad-MvP approach also provides a platform for the selection of immunodominant T-cell epitopes irrespective of the antigen source. This is of particular importance for large viruses, including EBV and CMV, which encode between 160-250 open reading frames. Overlapping peptide based approaches targeting single immunodominant antigens, such as CMV-pp65, have the potential to exclude immunodominant T-cell responses encoded by other antigens.
The capacity to fully characterize T-cell specificity and HLArestriction is likely to be of particular importance in the application of immunotherapy using allogeneic T-cell banks. This is particularly relevant for advanced stage development and formal implementation of these therapies in clinical settings. Allogeneic antigen-specific T-cell therapy, which is reliant upon the use of healthy seropositive blood donors to generate "off-the shelf" T-cell products, has been successfully employed in a number of clinical centers using both single and multivirus-specific T-cells. 18, 19 Using a xenogeneic EBV lymphoma model we demonstrated that allogeneic T-cells displayed a similar level of protection against tumor burden as that afforded by autologous T-cells. This was in spite of the fact that the allogeneic MvP-specific T-cell product matched only 50% of HLA class I alleles expressed by lymphoma cells.
Another potential application of the Ad-MvP is its use to prime virus-specific T-cell responses in seronegative transplant recipients prior to transplant. It has been suggested that vaccination of seronegative patients before transplant could provide protection against common infectious complications post-transplant. [31] [32] [33] [34] While a significant amount of preclinical and clinical research has been undertaken to explore the use of vaccination in transplant patients, particularly in the context of CMV, the capacity to induce T-cell memory against multiple potential infectious complications using a single vaccine vector has the potential to reduce the cost associated with developing a vaccine platform for each disease. Using a HLA transgenic mouse model, we demonstrated that Ad-MvP induced robust responses to multiple viruses that could be recalled and expanded following restimulation with viral peptide epitopes. These observations provide preclinical evidence that in addition to its potential use a platform to rapidly generate multivirus-specific T-cells, the Ad-MvP vector also has potential use as a vaccine vehicle to induce memory T-cell immunity against multiple viruses in a single dose.
Adoptive immunotherapy with either autologous or allogeneic HLA matched multivirus-specific T-cells has the potential to provide a simplified platform for the treatment of multiple infectious complications associated with organ transplantation. For this approach to be broadly applicable several criteria must be fulfilled including simple and rapid manufacturing protocols, broad HLA-coverage, targeting of multiple viral epitopes and effectiveness against more than one common pathogen. We have demonstrated that the Ad-MvP vector addresses all of the above criteria, and is therefore likely to be a valuable tool to make T-cell therapy readily available to treat viral complications after transplantation.
MATeRIAlS AND MeTHODS
Construction of multivirus adenoviral vector (Ad-MvP)
The amino acid sequence of the 32 contiguous HLA class-I restricted CD8 + T-cell epitopes as a polyepitope from CMV, EBV, ADV, and BKV (Table 2) was translated into the nucleotide sequence using human universal codon usage. These epitopes have been previously described. [35] [36] [37] [38] The nucleotide acid sequence encoding the polyepitope with Nhe I and Kpn I restriction sites at 5′ and 3′ respectively was cloned into the pShuttle expression vector. Following amplification, the expression cassette from pShuttle was subcloned into an Ad5F35 expression vector. The recombinant Ad5F35 vector was transfected into human embryonic kidney HEK293 cells, and recombinant adenovirus (referred to as Ad-MvP) stocks were produced in HEK293 cells (Figure 1) .
In vitro expansion of multivirus-specific T-cells
PBMCs were isolated from peripheral blood by Ficoll gradient, washed and resuspended in Roswell Park Memorial Institute (RPMI)-1640 supplemented with 10% foetal bovine serum (FBS) (growth medium) or revived from frozen stocks and rested for at least 1 hour at 37°C before being used in T-cell assays. The cells were divided into responder and stimulator cells at a responder to stimulator ratio of 2:1. The stimulator cells were infected with Ad-MvP at a multiplicity of infection of 10:1 for 1 hour at 37°C. Unbound virus particles were washed off and the stimulator cells were cocultured with the responder cells in the presence of different cytokines as indicated (interleukin-2, IL-2 = 
